Research Article
Lack of Association of C677T Methylenetetrahydrofolate Reductase Polymorphism with Breast Cancer Risk in Mali
Table 1
Distribution of C677T MTHFR polymorphism by clinicopathological characteristics in the breast cancer group.
| | Clinical parameter | C677T MTHFR | | N = 127 (%) | CC | CT | TT | X2 | |
| | Age of diagnosis | | | | | 1.45 | 0.48 | | ≤40 years | 69 (54.7) | 59 (85.5) | 9 (13.0) | 1 (1.4) | | | | >40 years | 57 (45.2) | 52 (91.2) | 5 (8.8) | — | | | | Localization of tumor | | | | | 2.63 | 0.62 | | Right breast | 43 (33.9) | 36 (83.7) | 6 (14.0) | 1 (2.3) | | | | Left breast | 75 (59.0) | 68 (90.7) | 7 (9.3) | — | | | | Bilateral | 9 (7.1) | 8 (88.9) | 1 (11.1) | — | | | | Use of contraceptives | | | | 2.83 | 0.24 | | | No | 89 (70.1) | 78 (87.6) | 11 (12.4) | — | | | | Yes | 38 (29.9) | 34 (89.5) | 3 (7.9) | 1 (2.6) | | | | Menopausal status | | | | | 7.22 | 0.12 | | Premenopausal | 17 (13.4) | 14 (82.4) | 2 (11.8) | 1 (5.9) | | | | Postmenopausal | 43 (33.8) | 37 (86.0) | 6 (14.0) | — | | | | Fertile women | 67 (52.8) | 61 (91.0) | 6 (9.0) | — | | | | Parity | | | | | 7.98 | 0.14 | | Nulliparity | 15 (11.8) | 13 (86.7) | 2 (13.3) | — | | | | Primiparity | 17 (13.4) | 15 (88.2) | 1 (5.9) | 1 (5.9) | | | | Multiparity | 95 (74.8) | 84 (88.4) | 11 (11.6) | — | | | | Family history of BC | | | | | 0.10 | 0.95 | | Yes | 10 (7.9) | 9 (90.0) | 1 (10.0) | — | | | | No | 117 (92.1) | 103 (88.0) | 13 (11.1) | 1 (0.9) | | | | Obesity | | | | | 1.25 | 0.53 | | Yes | 41 (32.3) | 35 (85.4) | 6 (14.6) | — | | | | No | 86 (67.7) | 77 (89.5) | 8 (9.3) | 1 (1.2) | | | | Smoking | | | | | 2.10 | 0.35 | | Passive smoking | 20 (15.7) | 16 (80.0) | 4 (20.0) | — | | | | No | 107 (84.3) | 96 (89.7) | 10 (9.3) | 1 (0.9) | | | | Histologic type | | | | | 0.84 | 0.65 | | IDC | 121 (95.3) | 106 (87.6) | 14 (11.6) | 1 (0.8) | | | | Others | 6 (4.7) | 6 (100.0) | — | — | | | | Tumor size | | | | | 3.92 | 0.68 | | T1 | 2 (1.6) | 2 (100.0) | — | — | | | | T2 | 28 (22.0) | 25 (89.3) | 3 (10.7) | — | | | | T3 | 80 (63.0) | 72 (90.0) | 7 (8.8) | 1 (1.3) | | | | T4 | 17 (13.4) | 13 (76.5) | 4 (23.5) | — | | | | Nodal involvement | | | | | | | | N0 | 72 (56.7) | 65 (90.3) | 7 (9.7) | — | 4.24 | 0.64 | | N1 | 39 (30.7) | 33 (84.6) | 5 (12.8) | 1 (2.6) | | | | N2 | 13 (10.2) | 12 (92.3) | 1 (7.7) | — | | | | N3 | 3 (2.4) | 2 (66.7) | 1 (33.3) | — | | | | Metastasis | | | | | 0.08 | 0.96 | | M0 | 119 (93.7) | 105 (88.2) | 13 (10.9) | 1 (0.8) | | | | M1 | 8 (6.3) | 7 (87.5) | 1 (12.5) | — | | |
|
|
IDC, invasive ductal carcinoma; X2, chi-squared test; P = value; N, number; BC, breast cancer; CC, wild type; CT, heterozygous; TT, mutant homozygous. Others: glycogen-rich clear cell carcinoma, lobular carcinoma in situ, moderately differentiated adenocarcinoma, and infiltrating adenocarcinoma. |
